KalVista Pharmaceuticals rises after FDA nod for Ekterly
Source: SeekingAlpha
2025-07-07 10:06:53 ET
More on KalVista Pharmaceticals, Pharming
- Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation
- Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
- KalVista: Poised For Rare Disease Transformation
- FDA's Makary sought to reject KalVista’s drug: report
- KalVista said FDA will not meet review date for sebetralstat
Read the full article on Seeking Alpha
For further details see:
KalVista Pharmaceuticals rises after FDA nod for Ekterly
Pharming Group N.V.
NASDAQ: PHAR
PHAR Trading
3.1% G/L:
$15.65 Last:
3,781 Volume:
$15.44 Open:
PHAR Latest News
PHAR Stock Data
$1,106,258,522
65,794,170
N/A
5
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
